Search results for "P PB"

showing 10 items of 405 documents

"Table 10" of "Measurement of very forward energy and particle production at midrapidity in pp and p-Pb collisions at the LHC"

2022

p-remnant side ZN signal normalized to MB value vs. average Ncoll in p-Pb collisions at 8.16 TeV

ZDCslow nucleonscentralityproton-nucleus collisions8160.0P PBVery forward energy
researchProduct

"Table 4" of "Measurement of very forward energy and particle production at midrapidity in pp and p-Pb collisions at the LHC"

2022

Pb-remnant side ZN signal normalized to MB value vs. ZN centrality percentile in p-Pb collisions at 8.16 TeV

ZDCslow nucleonscentralityproton-nucleus collisions8160.0P PBVery forward energy
researchProduct

"Table 8" of "Measurement of very forward energy and particle production at midrapidity in pp and p-Pb collisions at the LHC"

2022

Pb-remnant side ZN signal normalized to MB value vs. average Ncoll in p-Pb collisions at 8.16 TeV

ZDCslow nucleonscentralityproton-nucleus collisions8160.0P PBVery forward energy
researchProduct

"Table 6" of "Measurement of very forward energy and particle production at midrapidity in pp and p-Pb collisions at the LHC"

2022

p-remnant side ZN signal normalized to MB value vs. ZN centrality percentile in p-Pb collisions at 8.16 TeV

ZDCslow nucleonscentralityproton-nucleus collisions8160.0P PBVery forward energy
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

"Table 6" of "Measurement with the ATLAS detector of multi-particle azimuthal correlations in p+Pb collisions at $\sqrt{s_{NN}}$ =5.02 TeV"

2014

The second flow harmonic measured with the four-particle cumulants as a function of transverse momentum in the event activity bin of 40-55 GeV.

v2Inclusive5020.0Angular CorrelationNuclear ExperimentP PB --> CHARGED X
researchProduct

"Table 5" of "Measurement with the ATLAS detector of multi-particle azimuthal correlations in p+Pb collisions at $\sqrt{s_{NN}}$ =5.02 TeV"

2014

The second flow harmonic measured with the four-particle cumulants as a function of transverse momentum in the event activity bin of 25-40 GeV.

v2Inclusive5020.0Angular CorrelationNuclear ExperimentP PB --> CHARGED X
researchProduct

"Table 7" of "Measurement with the ATLAS detector of multi-particle azimuthal correlations in p+Pb collisions at $\sqrt{s_{NN}}$ =5.02 TeV"

2014

The second flow harmonic measured with the four-particle cumulants as a function of transverse momentum in the event activity bin of 55-80 GeV.

v2Inclusive5020.0Angular CorrelationNuclear ExperimentP PB --> CHARGED X
researchProduct

"Table 1" of "Measurement with the ATLAS detector of multi-particle azimuthal correlations in p+Pb collisions at $\sqrt{s_{NN}}$ =5.02 TeV"

2014

The second flow harmonic measured with the two-particle cumulants as a function of transverse momentum in the event activity bin of 25-40 GeV.

v2Inclusive5020.0Angular CorrelationNuclear ExperimentP PB --> CHARGED X
researchProduct

"Table 3" of "Measurement with the ATLAS detector of multi-particle azimuthal correlations in p+Pb collisions at $\sqrt{s_{NN}}$ =5.02 TeV"

2014

The second flow harmonic measured with the two-particle cumulants as a function of transverse momentum in the event activity bin of 55-80 GeV.

v2Inclusive5020.0Angular CorrelationNuclear ExperimentP PB --> CHARGED X
researchProduct